For research use only
| Cat No. | ABC-TC0415 |
| Product Type | Human Bone Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | Hs903.T |
Tumorigenecity: Isoenzyme: Histopathology: Subculture: Split ratio: Media change: Reverse transcritase: Production
Hs903.T is a human tumor cell line derived from an osteoid osteoma bone tumor of a 29-year-old female donor. This line exhibits adherent growth in standard culture and reflects neoplastic characteristics consistent with bone-derived tumor cells. It originates from the same individual as the paired skin-derived line HS903.SK. While osteoid osteomas are typically benign bone tumors, Hs903.T represents a tumor-derived cell model useful for studying bone tumor biology and tumor cell behavior in vitro. Key attributes include its tumor origin from bone tissue and its stable propagation in culture, making it suitable for investigations into tumor-related signaling, matrix interactions, and cell proliferation relevant to skeletal neoplasms. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | Hs903.T |
| Species | Human |
| Cat.No | ABC-TC0415 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bone Cancer Cell Lines |
Hs903.T cell line is used as an in vitro bone tumor model to study tumor cell proliferation, tumor-matrix interactions, and responses to therapeutic agents in bone-associated neoplasms. They support investigations into signal transduction pathways and drug sensitivity assays pertinent to bone tumor cell biology and preclinical oncology research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
